Unlocking longevity with GLP-1: A key to turn back the clock?
Maturitas · 2024
DOI: 10.1016/j.maturitas.2024.108028 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Maturitas, 2024. Verfasst von Vivek P Chavda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India. Electronic address: vivek.chavd…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Longevity, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 98 Literaturangaben.
Abstract (Originalsprache)
Traditionally known for managing blood sugar, GLP-1, a gut hormone, is emerging as a potential key to both lengthening lifespan and combating age-related ailments. While widely recognized for its role in blood sugar control, GLP-1 is increasingly recognized for its diverse effects on various biological pathways beyond glucose metabolism. Research across organisms and humans suggests that activating GLP-1 receptors significantly impacts cellular processes linked to aging. Its ability to boost mitochondrial function, enhance cellular stress resistance, and quell inflammation hints at its wider influence on aging mechanisms. This intricate interplay between GLP-1 and longevity appears to act through multiple pathways. One key effect is its ability to modulate insulin sensitivity, potentially curbing age-related metabolic issues like type 2 diabetes. Its neuroprotective properties also make it a promising candidate for addressing age-related cognitive decline and neurodegenerative diseases. Furthermore, preclinical studies using GLP-1 analogs or agonists have shown promising results in extending lifespan and improving healthspan in various model organisms. These findings provide a compelling rationale for exploring GLP-1-based interventions in humans to extend healthy aging. However, despite the exciting therapeutic prospects of GLP-1 in promoting longevity, challenges remain. Determining optimal dosages, establishing long-term safety profiles, and investigating potential adverse effects require comprehensive clinical investigations before we can confidently translate these findings to humans. This article emphasises the wide applicability of GLP-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India. Electronic address: vivek.chavda@lmcp.ac.in.
- Pharmacy Section, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India.
Zitieren
APA
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024). Unlocking longevity with GLP-1: A key to turn back the clock?. Maturitas. https://doi.org/10.1016/j.maturitas.2024.108028
Vancouver
Chavda VP, Balar PC, Vaghela DA, Dodiya P. Unlocking longevity with GLP-1: A key to turn back the clock?. Maturitas. 2024. doi:10.1016/j.maturitas.2024.108028
BibTeX
@article{Chavda2024,
author = {Chavda, Vivek P and Balar, Pankti C and Vaghela, Dixa A and Dodiya, Payal},
title = {Unlocking longevity with GLP-1: A key to turn back the clock?},
journal = {Maturitas},
year = {2024},
doi = {10.1016/j.maturitas.2024.108028}
}
EUVIMED